Next Article in Journal
Cancer Narratives: Words beyond Disease—A Call for Submissions
Previous Article in Journal
New Chart Review Data Validate Administrative Data–Based Indicator for Guideline-Recommended Treatment of Locally Advanced Non-Small-Cell Lung Cancer and Shed Light on Reasons for Non-Referral and Non-Treatment
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 20
Issue 2
10.3747/co.20.1315
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Informing Canada’s Cancer Drug Funding Decisions with Scientific Evidence and Patient Perspectives: The Pan-Canadian Oncology Drug Review

by
J.S. Hoch
1,* and
M. Sabharwal
2
1
Pharmacoeconomics Research Unit, Cancer Care Ontario, and Canadian Centre for Applied Research in Cancer Control, Toronto, ON, Canada
2
Pan-Canadian Oncology Drug Review, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2013, 20(2), 121-124; https://doi.org/10.3747/co.20.1315
Submission received: 2 January 2013 / Revised: 3 February 2013 / Accepted: 4 March 2013 / Published: 1 April 2013

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

JSH: In July 2011, the pan-Canadian Oncology Drug Review [pcodr (http://www.pcodr.ca/)] began accepting submissions by pharmaceutical manufacturers and clinician-based tumour groups to have cancer drugs reimbursed by provincial payers in Canada. Doesn’t Canada already have a body reviewing drugs? [...]

Share and Cite

MDPI and ACS Style

Hoch, J.S.; Sabharwal, M. Informing Canada’s Cancer Drug Funding Decisions with Scientific Evidence and Patient Perspectives: The Pan-Canadian Oncology Drug Review. Curr. Oncol. 2013, 20, 121-124. https://doi.org/10.3747/co.20.1315

AMA Style

Hoch JS, Sabharwal M. Informing Canada’s Cancer Drug Funding Decisions with Scientific Evidence and Patient Perspectives: The Pan-Canadian Oncology Drug Review. Current Oncology. 2013; 20(2):121-124. https://doi.org/10.3747/co.20.1315

Chicago/Turabian Style

Hoch, J.S., and M. Sabharwal. 2013. "Informing Canada’s Cancer Drug Funding Decisions with Scientific Evidence and Patient Perspectives: The Pan-Canadian Oncology Drug Review" Current Oncology 20, no. 2: 121-124. https://doi.org/10.3747/co.20.1315

APA Style

Hoch, J. S., & Sabharwal, M. (2013). Informing Canada’s Cancer Drug Funding Decisions with Scientific Evidence and Patient Perspectives: The Pan-Canadian Oncology Drug Review. Current Oncology, 20(2), 121-124. https://doi.org/10.3747/co.20.1315

Article Metrics

Back to TopTop